ProQR Therapeutics 株価情報 (NASDAQ: PRQR)

最新ニュース ProQR Therapeutics (NASDAQ:PRQR) 株価情報

ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

News

Price Target

Reiteration

Analyst Ratings

PRQR

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $4 price target.

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target

ProQR Therapeutics NV. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer&#x2122; RNA editing technology platform, today announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Dsx1RiYqkjHBqb-lIkrSz2noMHoflfEI6btUa5AtkqPvx44ToZUwX37L-qvo05YjUcobTuHcv2m6m80srRqEsejWR4fwMwJ6Qz9UTOOd-lJGLyUF_8EQqBLN8nx_nvgxX19EI-ejBu2ocglEdDjMEaESNxXEnBl7A7SxsWJpeaJ53yHbZYFWqpddNu56USLp8n2l5UV9ZjYb328G6vb1zWJftnlabPl6YZZstTfVX1WQVALgNUUOr5qVK6XaRA_SV0RSXz1cHqWFLfKic6qEmfND5naYM3qrO1MJXTPkhMg=">initial $1 million research grant announced in January 2024</a>,&nbsp;the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials.
Rett Syndrome, a rare and devastating neurodevelopmental disorder, affects approximately 350,000 people worldwide, predominantly girls. With no current cures and limited treatment options, Rett Syndrome presents a significant unmet medical need. AX-2402 is being developed for individuals with Rett syndrome who have the R270X mutation in MECP2 gene, and is based on ProQR's proprietary Axiomer RNA editing platform. Axiomer can target many mutations beyond R270X that collectively impact a large segment of the Rett population. Success with AX-2402 sets the foundation for developing RNA editing therapeutics to target the remaining mutations.

ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett <a href="https://www.benzinga.com/quote/NGNE">syndrome patient</a>.
Neurogene shares declined 37.7% to $21.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares tumbled 16.1% to $2.29 in pre-market trading after dipping over 20% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) tumbled 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares fell 7% to $6.28 in pre-market trading.</li>
<li>CompoSecure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) shares declined 5.9% to $13.00 in pre-market trading.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 5.4% to $266.21 in pre-market trading following a 4% decline on Friday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 5% to $11.80 in pre-market trading after jumping 21% on Friday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 4% to $3.67 in pre-market trading.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.4% to $138.51 in pre-market trading after declining more than 3% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMAT

AMGN

CMPO

LAZR

LUNR

NGNE

NVDA

OMER

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

WIIM

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

HC Wainwright &amp; Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $5 to $10.

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $10

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Renata Cabral upgraded the rating for Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) from Neutral to Buy and raised the price target from $93 to $102. Coca-Cola Femsa shares closed at $84.40 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Sean Milligan upgraded the rating for First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Neutral to Buy and announced a $260 price target. First Solar shares closed at $205.03 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dormois upgraded Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) from Underperform to Hold. Philips shares closed at $26.62 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and boosted the price target from $6 to $14. ProQR Therapeutics shares closed at $3.31 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adam Seiden upgraded the rating for Summit Materials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Equal-Weight to Overweight and raised the price target from $45 to $52. Summit Materials shares closed at $45.63 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FSLR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png" alt="" class="wp-image-619521" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a></li>
</ul>

Upgrades

FSLR

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and raises the price target from $6 to $14.

Raymond James Upgrades ProQR Therapeutics to Strong Buy, Raises Price Target to $14

Reported Earlier, ProQR Secures $75M Through Public Offering And Private Placement With Strategic Partner Eli Lilly

All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional&nbsp;15%&nbsp;of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions.
ProQR intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to primarily fund research and development and clinical development to support the advancement of its current or future product candidates and the expansion of its research and development programs, and the remainder for working capital, capital expenditures and other general corporate purposes.

Offerings

ProQR Therapeutics Commences Public Offering Of Its Ordinary Shares; No Terms Disclosed

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

BEKE

CAPR

CERS

LCID

LILM

MNSO

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) rose sharply in today's pre-market trading following <a href="https://www.benzinga.com/news/earnings/24/10/41373163/nvidia-supplier-tsmc-reports-q3-revenue-earnings-beat-amid-rising-demand-for-ai-chips">better-than-expected quarterly results.</a>
TSMC reported consolidated third-quarter revenue of NT$759.69 billion ($23.50 billion), up 39% year-over-year. Sequentially, the top line expanded by 12.8%. In dollar terms, the revenue growth was 36% year-over-year and 12.9% quarter-over-quarter. Revenue topped the NT$748 billion consensus, as provided by Bloomberg.
Taiwan Semiconductor Manufacturing shares jumped 8.1% to $202.75 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) rose 354.4% to $6.27 in pre-market trading after gaining over 7% on Wednesday.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) gained 165.7% to $5.90 in pre-market trading after jumping around 128% on Wednesday.</li>
<li>Brera Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BREA#NASDAQ">BREA</a>) shares surged 144.1% to $1.70 in pre-market trading.</li>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) gained 105% to $0.6672 in pre-market trading. Molecular Templates recently announced it approved the liquidation and wind-up of the company.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) rose 61.3% to $2.71 in pre-market trading after jumping 24% on Wednesday.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) shares jumped 36.9% to $3.08 in pre-market trading after the company announced it secured a DOE conditional commitment loan of $1.46 billion for its net-zero 1 sustainable aviation fuel plant in South Dakota.</li>
<li>Klotho Neurosciences, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) climbed 29.9% to $0.7297 in pre-market trading after jumping 15% on Wednesday. Klotho Neurosciences recently tapped Peter Moriarty of Shire Pharma as COO.</li>
<li>Fresh Vine Wine, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VINE#NYSE">VINE</a>) shares rose 22.4% to $0.97 in pre-market trading after gaining around 7% on Wednesday. The company recently announced the acquisition of Adifex.</li>
<li>Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) gained 21.7% to $26.69 in pre-market trading after the company announced its subsidiary, Montana Renewables secured a $1.44 billion conditional commitment from the DOE for renewable fuels and biomass energy facility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) shares dipped 38.5% to $1.66 in pre-market trading after jumping around 647% on Wednesday.</li>
<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 29.1% to $4.59 in pre-market trading. 180 Life Sciences shares jumped 325% on Wednesday after the company announced it is planning to enter the online gaming industry with its newly acquired gaming technology platform.</li>
<li>Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) fell 29.1% to $2.79 in today's pre-market trading. Versus Systems shares jumped 250% on Wednesday after the company announced a $2.5 million investment and licensing agreement with ASPIS.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) fell 25.1% to $0.4710 in pre-market trading. Carmell shares surged around 68% on Wednesday after the company in a FormRW filing disclosed that it decided to not pursue the offering due to business decisions and confirmed that no securities covered by the Registration Statement have been issued or sold and that the SEC did not declare the Registration Statement effective.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares declined 22.4% to $1.11 in pre-market trading after jumping 55% on Wednesday. Fangdd Network Group, last week, said it regained compliance status with the Nasdaq regarding its minimum bid price requirement.</li>
<li>Quoin Pharmaceuticals, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) declined 20.2% to $0.6291 in pre-market trading after jumping 56% on Wednesday.</li>
<li>SAIHEAT Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIH#NASDAQ">SAIH</a>) shares fell 19.8% to $0.7570 after jumping 64% on Wednesday.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares declined 16.6% to $0.0500 in pre-market trading after falling over 12% on Wednesday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) fell 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

ATNF

BREA

CLMT

CTCX

EFSH

GEVO

GRTS

KLTO

MTEM

QNRX

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Pro QR Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.

Earnings

ProQR Therapeutics Q1 2024 GAAP EPS €(0.03) Beats €(0.11) Estimate, Sales €6.305M Miss €11.460M Estimate, €96.2M Cash Position As Of End Of Q2 Providing Runway Into Mid-2026

ProQR Therapeutics NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. &nbsp;
As part of the conference program, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, will present on June 20, 2024 at 2:00pm ET:

Biotech

General

ProQR Presents Its Axiomer RNA Editing Technology At RNA Editing Summit

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $2.5 price target.

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $5 price target.

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

Guidance

Health Care

ProQR Therapeutics' Cash And Cash Equivalents And Short Term Financial Assets Of €102.7M As Of End Of Q1 Provides Runway Into Mid-2026

ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate

ProQR (PRQR) has released an update. ProQR Therapeutics is set to engage investors and analysts with a virtual event on December 11, where it will ...

ProQR Highlights RNA Innovations in Upcoming Event

ProQR Therapeutics (PRQR) announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief AD...

ProQR Therapeutics appoints Beal as Chief ADAR Scientist

ProQR (PRQR) has released an update. ProQR Therapeutics has appointed Dr. Peter Beal as Chief ADAR Scientist, enhancing their capabilities in RNA e...

ProQR Strengthens RNA Editing Team with Key Appointment

ProQR Therapeutics (PRQR) announced an expansion of its collaboration with the Rett Syndrome Research Trust, RSRT. Building on the initial $1 milli...

ProQR Therapeutics announces $8.1M in new funding from RSRT

ProQR ( ($PRQR) ) just unveiled an announcement. ProQR Therapeutics announced significant advancements in their Axiomer RNA-editing platform during...

ProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic Partnerships

ProQR (PRQR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP Sec...

ProQR's Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy Rating

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $4.00...

ProQR's Strategic Advancements and Financial Stability Drive 'Buy' Rating

Oppenheimer analyst Andreas Argyrides initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $15 price target The firm says ...

ProQR Therapeutics initiated with an Outperform at Oppenheimer

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on ProQR (PRQR – Research Report) today and set a price target of $8.00. Jonathan ...

Comments

ProQR Therapeutics

ニュース

最新ニュース ProQR Therapeutics (NASDAQ:PRQR) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル